Shots: Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple […]Read More
Shots: AstraZeneca & Merck will utilize Myriads’ BRAC Analysis CDx to identify germline BRCA mutations in men who have mCRPC cancer, enrolled in Phase III PROfound (NCT02987543) study In 2007, Myriad collaborates with AZ for BRAC Analysis CDx to be used as a companion diagnostic to Lynparza (olaparib) and the combination has received approval from […]Read More
Shots: Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene In April, 2015 Myriad and […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
